

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]

Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R. *Ther Clin Risk Manag.* 2022;18:699–719.

The authors have advised there is an error in Table 1 on page 712. The value “1200 mg” in the *Neisseria meningitidis* vaccination row for the Induction Phase, Week 4 column for Refractory gMG Adult (≥ 18 years of age) Dosing Schedule, should read “900 mg”.

This error was introduced by the Editorial staff during the publication process.

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>